Methodological approaches for overcoming regulatory challenges through early FDA engagement
This paper describes some of the more salient regulatory challenges involved in determining the appropriateness and legitimacy of a possible target involving cognitive impairment associated with various CNS disorders and how to overcome these drug development challenges.
